4.4 Article

Bile acids regulate intestinal antigen presentation and reduce graft-versus-host disease without impairing the graft-versus-leukemia effect

Journal

HAEMATOLOGICA
Volume 106, Issue 8, Pages 2131-2146

Publisher

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2019.242990

Keywords

-

Categories

Funding

  1. Else Kroner-Fresenius-Stiftung [EKFS 2015_A147]
  2. INTERREG V European regional development fund (European Union) program
  3. Wilhelm Sander Stiftung [2008.046.5]
  4. Deutsche Forschungsgemeinschaft, Germany [SFB1160, SFB850]
  5. ERC Consolidator grant (GvHDCure European Union) [681012]
  6. Excellence Strategy of the German Federal and State Governments (CIBSS) [EXC 2189]
  7. Berta Ottenstein Program for Physician Scientists, Faculty of Medicine, Medical Center -University of Freiburg, Germany
  8. German Federal Ministry of Education and Research (BMBF) [FKZ 01ZX1708F, FKZ 01ZZ1606A-H]
  9. Deutsche Forschungsgemeinschaft (DFG), under Germany's Excellence Strategy [SFB1160/2_B5, CIBSS -EXC-2189, 390939984, RESIST -EXC 2155, 39087428]
  10. EU
  11. DFG [GR1617/141/iPAD]
  12. Netzwerke Seltener Erkrankungenof the German Ministry of Education and Research (BMBF) [GAIN_01GM1910A]
  13. European Research Council (ERC) [681012] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

Bile acids play a role in preventing acute GvHD by protecting the intestinal epithelium without compromising the immune therapy effect, providing a new treatment option for patients undergoing allogeneic hematopoietic cell transplantation.
Acute graft -versus -host disease (GvHD) causes significant mortality in patients undergoing allogeneic hematopoietic cell transplantation. Immunosuppressive treatment for GvHD can impair the beneficial graft -versus -leukemia effect and facilitate malignancy relapse. Therefore, novel approaches that protect and regenerate injured tissues without impeding the donor immune system are needed. Bile acids regulate multiple cellular processes and are in close contact with the intestinal epithelium, a major target of acute GvHD. Here, we found that the bile acid pool is reduced following GvHD induction in a preclinical model. We evaluated the efficacy of bile acids to protect the intestinal epithelium without reducing anti-tumor immunity. We observed that application of bile acids decreased cytokine-induced cell death in intestinal organoids and cell lines. Systemic prophylactic administration of tauroursodeoxycholic acid (TUDCA), the most potent compound in our in vitro studies, reduced GvHD severity in three different murine transplantation models. This effect was mediated by decreased activity of the antigen presentation machinery and subsequent prevention of apoptosis of the intestinal epithelium. Moreover, bile acid administration did not alter the bacterial composition in the intestine suggesting that its effects are cell-specific and independent of the microbiome. Treatment of human and murine leukemic cell lines with TUDCA did not interfere with the expression of antigen presentation-related molecules. Systemic T-cell expansion and especially their cytotoxic capacity against leukemic cells remained intact. This study establishes a role for bile acids in the prevention of acute GvHD without impairing the graft -versus -leukemia effect. In particular, we provide a scientific rationale for the systematic use of TUDCA in patients undergoing allogeneic hematopoietic cell transplantation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available